Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATG-100
- Development stage
- Preclinical
- Lead developer
- Ategenos Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Transdermal
01
Overview
ATG-100 is an investigational transdermal drug delivery system developed by Ategenos Pharmaceuticals for the treatment of cardiovascular disease. The product utilizes Ategenos's proprietary SmartPatch technology to deliver an existing, previously approved branded therapy. A key feature of the ATG-100 system is its integrated real-time adherence monitoring, which allows healthcare providers to track patient compliance. By transitioning an oral or existing therapy to a transdermal patch with digital monitoring, the system aims to improve the pharmacokinetic profile and ensure better adherence in patients with chronic cardiovascular conditions.
Beyond the preview
Go deeper on ATG-100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATG-100.